Home

Hassy Heldin Farbe doi 10.1093 ecco jcc jjx009 Auspacken Vermuten Kilimanjaro

Frontiers | Gastroenterologists Adherence to Tumor Necrosis Factor  Antagonist Combination Therapy in Inflammatory Bowel Disease
Frontiers | Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease

Advances in Clinical and Experimental Medicine
Advances in Clinical and Experimental Medicine

Frontiers | Dehydrocostus Lactone Suppresses Dextran Sulfate Sodium-Induced  Colitis by Targeting the IKKα/β-NF-κB and Keap1-Nrf2 Signalling Pathways
Frontiers | Dehydrocostus Lactone Suppresses Dextran Sulfate Sodium-Induced Colitis by Targeting the IKKα/β-NF-κB and Keap1-Nrf2 Signalling Pathways

Ulcerative colitis progression: a retrospective analysis of disease burden  using electronic medical records | Upsala Journal of Medical Sciences
Ulcerative colitis progression: a retrospective analysis of disease burden using electronic medical records | Upsala Journal of Medical Sciences

Third European Evidence-based Consensus on Diagnosis and Management of  Ulcerative Colitis. Part 2: Current Management | Journal of Crohn's and  Colitis | Oxford Academic
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management | Journal of Crohn's and Colitis | Oxford Academic

Frontiers | Inflammatory Indexes for Assessing the Severity and Disease  Progression of Ulcerative Colitis: A Single-Center Retrospective Study
Frontiers | Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study

Frontiers | The Communication Between Intestinal Microbiota and Ulcerative  Colitis: An Exploration of Pathogenesis, Animal Models, and Potential  Therapeutic Strategies
Frontiers | The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies

PDF) Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal  Inflammation and Disease Activity in Ulcerative Colitis
PDF) Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis

PDF) Corrigendum: Third European Evidence-based Consensus on Diagnosis and  Management of Ulcerative Colitis. Part 2: Current Management
PDF) Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challeng | CEG
Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challeng | CEG

Frontiers | Role of Eosinophils in Intestinal Inflammation and Fibrosis in  Inflammatory Bowel Disease: An Overlooked Villain?
Frontiers | Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?

Frontiers | Hericium erinaceus, in combination with natural  flavonoid/alkaloid and B3/B8 vitamins, can improve inflammatory burden in  Inflammatory bowel diseases tissue: an ex vivo study
Frontiers | Hericium erinaceus, in combination with natural flavonoid/alkaloid and B3/B8 vitamins, can improve inflammatory burden in Inflammatory bowel diseases tissue: an ex vivo study

Ulcerative colitis progression: a retrospective analysis of disease burden  using electronic medical records
Ulcerative colitis progression: a retrospective analysis of disease burden using electronic medical records

The long-term effect of biologics in patients with ulcerative colitis  emerging from a large Japanese cohort | Scientific Reports
The long-term effect of biologics in patients with ulcerative colitis emerging from a large Japanese cohort | Scientific Reports

Genetic and dietary modulators of the inflammatory response in the  gastro-intestinal tract of the BXD mouse genetic reference population
Genetic and dietary modulators of the inflammatory response in the gastro-intestinal tract of the BXD mouse genetic reference population

Living with Ulcerative Colitis Study (LUCY) in England: a retrospective  study evaluating healthcare resource utilisation and direct healthcare  costs of postoperative care in ulcerative colitis | BMJ Open  Gastroenterology
Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis | BMJ Open Gastroenterology

Genetic and dietary modulators of the inflammatory response in the  gastro-intestinal tract of the BXD mouse genetic reference population
Genetic and dietary modulators of the inflammatory response in the gastro-intestinal tract of the BXD mouse genetic reference population

Frontiers | Thiopurines in Inflammatory Bowel Disease. How to Optimize  Thiopurines in the Biologic Era?
Frontiers | Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era?

PDF) Third European Evidence-based Consensus on Diagnosis and Management of  Ulcerative Colitis. Part 2: Current Management
PDF) Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

Frontiers | Management of Non-response and Loss of Response to Anti-tumor  Necrosis Factor Therapy in Inflammatory Bowel Disease
Frontiers | Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

Journal of Prescribing Practice - Nurse-led early evaluation following  corticosteroid prescription in patients with inflammatory bowel disease
Journal of Prescribing Practice - Nurse-led early evaluation following corticosteroid prescription in patients with inflammatory bowel disease

Frontiers | Natural Anti-Inflammatory Compounds as Drug Candidates for  Inflammatory Bowel Disease
Frontiers | Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease

Frontiers | Investigating dysbiosis and microbial treatment strategies in  inflammatory bowel disease based on two modified Koch's postulates
Frontiers | Investigating dysbiosis and microbial treatment strategies in inflammatory bowel disease based on two modified Koch's postulates

Frontiers | The IL23-IL17 Immune Axis in the Treatment of Ulcerative  Colitis: Successes, Defeats, and Ongoing Challenges
Frontiers | The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges

Neutrophil-to-lymphocyte ratio may predict clinical relapse in ulcerative  colitis patients with mucosal healing
Neutrophil-to-lymphocyte ratio may predict clinical relapse in ulcerative colitis patients with mucosal healing

Frontiers | Inflammatory Indexes for Assessing the Severity and Disease  Progression of Ulcerative Colitis: A Single-Center Retrospective Study
Frontiers | Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study

Subcutaneous Infliximab Monotherapy Versus Combination Therapy with  Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a  Randomised Clinical Trial | Clinical Drug Investigation
Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial | Clinical Drug Investigation